The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 1566)
LRRK2 Biology Consortium, 2018
Parkinson's disease (PD) affects nearly any body system, as evidenced by the diversity of its symptoms. While its non-motor symptoms, such as olfactory dysfunction, rapid eye movement sleep behavior disorder (RBD) and gastrointestinal (GI) abnormalities, do not define the disease, they have a large impact on those living with it. In this project, we will use a pre-clinical model o...
Researchers: R. Jeremy Nichols, PhD
Target Validation, 2017
Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release
Synucleinopathies, including Parkinson's disease (PD), are a family of central nervous system (CNS) degenerative disorders characterized by alpha-synuclein protein-containing aggregates. Toll-like receptors (TLRs), which includes TLR2, play a critical role in the immune system's response to foreign pathogens that can trigger adverse inflammatory signaling. Recently, alpha-synuclein...
Researchers: Martin B. Gill, PhD
Improved Biomarkers & Clinical Outcome Measures, 2017
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time and lets it "leak" into the brain when needed. This levodopa reservoir appears to get "leakier" as PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we...
Researchers: Kevin J. Black, MD
Research Grant, 2017
Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative parkinsonian syndromes in clinical trials and studies. Distance, disability and the distribution of movement disorder specialists and research centers limits participation of individuals with PD and other degene...
Therapeutic Pipeline Program, 2017
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB, a neuroprotective receptor. We have screened several independent chemical series of a type of chemical compounds, called TrkB PAMs, which can become optimized (improved) to become potential Parkinso...
Researchers: Robert Lutjens, PhD